Susquehanna International Group’s IRulya Therapeutics Inc. Common Stock IRLA Stock Holding History

Susquehanna International Group’s Portfolio IRLA Stock Details IRLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-55	Closed	-$1.1K	–	14308
2026 Q1	$1.1K	Buy	+55	New	+$11K	﹤0.01%	13028
2022 Q4	–	Sell	-323	Closed	-$86K	–	13436
2022 Q3	$86K	Sell	323 -104	-24%	-$39.6K	﹤0.01%	11818
2022 Q2	$190K	Sell	427 -717	-63%	-$507K	﹤0.01%	10710
2022 Q1	$1.42M	Sell	1,144 -836	-42%	-$1.14M	﹤0.01%	6284
2021 Q4	$5M	Sell	1,980 -130	-6%	-$793K	﹤0.01%	3738
2021 Q3	$38.7M	Buy	2,110 +1,196	+131%	+$19M	0.01%	1351
2021 Q2	$9.68M	Sell	914 -123	-12%	-$1.03M	﹤0.01%	2967
2021 Q1	$7.47M	Buy	1,037 +271	+35%	+$1.95M	﹤0.01%	3247
2020 Q4	$4.25M	Buy	766 +736	+2,453%	+$6.52M	﹤0.01%	3690
2020 Q3	$295K	Buy	+30	New	+$273K	﹤0.01%	8740

Other funds holding IRLA

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Susquehanna International Group's IRLA Position: Q2 2026 in Review

Susquehanna International Group sold out of IRulya Therapeutics Inc. Common Stock (IRLA) in Q2 2026, closing a stake of 863 shares — an estimated $19.8K sold.

Susquehanna International Group first reported a position in IRLA in Q1 2021 and held it in 17 quarters. The position peaked at $6.12M in Q4 2021. 26 funds tracked by Wall St. Rank hold IRLA as of Q2 2026.

Susquehanna International Group reported no remaining IRulya Therapeutics Inc. Common Stock position as of Q2 2026 after selling out during the quarter.
Susquehanna International Group sold 863 IRulya Therapeutics Inc. Common Stock shares in Q2 2026, an estimated $19.8K.
Susquehanna International Group first reported a position in IRulya Therapeutics Inc. Common Stock in Q1 2021 and held it in 17 quarters.
Susquehanna International Group's IRulya Therapeutics Inc. Common Stock position peaked at $6.12M in Q4 2021.
26 funds tracked by Wall St. Rank held IRulya Therapeutics Inc. Common Stock as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.